# Eirion Therapeutics

AI-09 — a ready-to-use liquid injectable recombinant BoNT-A — achieved clinically and statistically significant results with a 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial (October 2024, four US investigational sites), entered Phase 2 (NCT07321834) in December 2025;…

Source: https://en.bioecon.ru/companies/eirion-therapeutics/
Updated: 2026-08-15

- Country: United States

## Technologies

- [Recombinant botulinum toxin (biosynthetic Botox)](https://en.bioecon.ru/technology/recombinant-botulinum-toxin/)